EFFICACY OF TREATMENT OF INTRAVESICAL CHEMOTHERAPY IN NONINVASIVE MUSCULAR BLADDER CANCER
Abstract
Bladder cancer is the second most common tumor among all neoplasms of the genitourinary tract in the world. The most common is urothelial (transitional cell) RMP, which accounts for up to 90- 95% of all bladder tumors. In most cases, treatment of superficial bladder cancer begins with transurethral resection (TUR). Depending on the characteristics of the group of patients and the duration of follow-up, up to 80% of surface tumors recur and 2-50% progress to a muscle-invasive tumor. Intravesical therapy is currently widely used to prevent recurrence and, less often, to treat superficial bladder cancer. Along with the surgical removal of the tumor, it is necessary to carry out treatment aimed at preventing relapses and preventing progression. For this purpose, intravesical chemotherapy (VPHT) or immunotherapy is used. The most effective drugs in the near-surface RMP are adriamycin (doxorubicin), pharmarubicin (epirubicin). Thus, VPHT is widely used in the treatment of patients with superficial RMP.